Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Neurology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Alzheimer's Disease Clinical Trials

A listing of Alzheimer's Disease medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (53) clinical trials

The purpose of this study is to evaluate the effect of pioglitazone at 24 months compared with placebo on cognitive decline in high-risk participants who have completed the AD-4833/TOMM40_301 study [NCT01931566] with an adjudicated diagnosis of mild cognitive impairment (MCI) due to Alzheimer's Disease (AD).

Phase

The purpose of this study is to provide subjects who have completed participation in a Phase 2 or Phase 3 trial with TRx0237 continued access to therapy and to evaluate the long-term safety of TRx0237.

Phase

To establish efficacy of Lu AE58054 as adjunctive therapy to acetylcholinesterase inhibitors (AChEIs) for symptomatic treatment of patients with mild-moderate Alzheimer's disease (AD).

Phase

The primary objective of the study is to evaluate the efficacy of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) score as compared with placebo in participants with early AD. Secondary objectives are to assess the ...

Phase

The purpose of this trial is to assess the efficacy and safety of MK-8931 compared with placebo in the treatment of amnestic mild cognitive impairment (aMCI) due to Alzheimer's Disease (AD), also known as prodromal AD. Participants will be randomized to receive placebo, or 12 mg or 40 mg MK-8931, ...

Phase

52 week duration Lab testing physical exams mental scales PET and MRI scans

Phase

Researchers are conducting a local research study for an investigational drug in people with mild Alzheimer's disease.

Phase

EXPEDITION 3 will look at whether the investigational drug solanezumab can help slow the worsening of AD in patients with mild disease. Study duration will be approximately 18 months, followed by an optional open-label extension study. Participants will be randomized in a 1:1 ratio to receive solanezumab or placebo by ...

Phase

Patient Inclusion Criteria: Ages: over 66-85 Male/Female 26 Double Blind Period, Optional 26 week Long Extension No History of Cancer within past 5 years Dementia status of mild to moderate CT or MRI scan within 18 months prior to screening compatible with a diagnosis of probable Alzheimer's disease Score on ...

Phase

NeuroTrials Research is conducting a 20-month, placebo-controlled research study evaluating an investigational drug for Alzheimer’s Disease. Study-related exams and study drug are provided at no cost. Qualified participants and caregivers will be compensated for time and travel. Patient Inclusion Criteria: Age 50-89 Diagnosis of probable Alzheimer’s Disease Must have a ...

Phase